TipRanks
The bottom is available for these two stocks? Analysts say ‘buy’
Today, we look at two small-cap biotech ventures whose stocks have hit a notch. Each company recently experienced a clinical setback that caused the share price to fall, erasing previous gains and falling back to low levels. Setbacks of this kind do not occur uncommon in the biotechnology industry, and in fact emphasize the risk and speculative nature of the industry. So what should investors do if a stock collapses? Is it a matter of poor fundamentals? And has the share price found its low point? This is where the Wall Street pros come in. Noting that everyone is planning to start upward trajectories, some five-star analysts see an attractive entry point for both. Using TipRanks’ database, we found that these two ticks earned consensus ratings of Moderate or Strong Buy from the analyst community, and that they have strong upside potential. Cortexyme, Inc. (CRTX) The first hit name we look at is Cortexyme, a biopharma company in a clinical stage focused on degenerative diseases, especially Alzheimer’s. The company’s main candidate is COR388, also called atuzaginstat. Atuzaginstat is currently being investigated in the GAIN trial, a study of its efficacy against Alzheimer’s disease. The trial was fully enrolled, with 643 patients, and the company moved toward an open label enrollment (OLE) portion of the Phase 2/3 study. During a routine update of the regulations, Cortexyme announced that the OLE phase will be discontinued, although the primary GAIN study will continue, with results to be announced in Q4 2021. The announcement of the partial strike caused a 35% drop in the share price. The partial hold was caused by adverse events on the liver during the atuzaginstat trial. The liver symptoms were reversible and had no long-term consequences. The FDA has revised these records, and in collaboration with Cortexyme it has been decided to keep the OLE while continuing with GAIN. With this decision, the main issue of the program can continue while a new protocol for the OLE is worked out. The purpose of the OLE is to test the long-term effectiveness and tolerance of the drug. In a review of Cortexyme after the announcement, HC Wainwright’s 5-star analyst Andrew Fein remarked: ‘Cortexyme’s announcement of a partial clinical hold on the OLE study of atuzaginstat is disappointing, but the reversible nature of liver toxicity may be’ offers some hope for Cortexyme. We believe that the continuation of the core trial indicates that the drug-induced liver injury may not be serious enough to stop the program. As for the short term, Fein adds: ‘The continuation of the GAIN trial is encouraging despite the partial hold on OLE. This suggests that the FDA intends to wait for the additional details of the nuclear trial before reaching a conclusion. Management said nearly one-third of GAIN patients completed the study and were past the twelve-week mark, indicating they were out of risk. For this purpose, Fein CRTX is evaluating a buy, and its price target of $ 76 indicates confidence in a growth potential of 147%. (To view Fein’s record, click here. Overall, Cortexyme has a moderate buy rating from the analyst’s consensus, with six recent reviews ranging from 4 to 1 to 1, Buy-Hold-Sell. The stock’s average price target of $ 83.60 indicates that Wall Street sees great potential here, at about 170% higher than the trading price of $ 30.74. (See CRTX stock analysis on TipRanks) Immunovant (IMVT) Next is Immunovant, a clinical stage biopharmaceutical research firm, focusing on the development of treatments for patients with autoimmune disorders, a class of diseases in which the immune system attacks the patient’s own body.The firm’s principal drug candidate, IMVT-1401, is undergoing trials as a treatment for thyroid eye disease, myasthenia gravis and hot autoimmune hemolytic anemia, described as a new, fully human anti-FcRn monoclonal antibody delivered by subcutaneous injection On February 2, Immunovant’s evening eel fell by 42%, and it has since fallen. The precipitation factor was an announcement by the company that IMVT-1401 had temporarily discontinued its clinical phase 2b for thyroid eye diseases due to patients experiencing dangerous increases in their LDL levels. LDLs are the potentially harmful form of cholesterol associated with cardiovascular disease. Despite the clinical setback, Stiffel’s 5-star analyst Derek Archila reiterated a buy rating on IMVT shares, coupled with a price target of $ 28. This figure indicates an upward potential of 52% from current levels. (Click here to view Archila’s record.) ‘Interestingly, only increases have been seen in TED patients, and our review of the literature suggests a few things: (1) it is likely to be TED-specific, given the biology – see below for details, but we do not think similar LDL increases will be seen in other indications outside of TED; and (2) other anti-thyroid therapies used in Graves / TED also see similar increases in LDL, which are ultimately transient in nature. We think IMVT-1401 is repeating this mechanism, “the analyst remarked. Archila summed up:” Although we will need to see additional data from the company to confirm … we do not think this program is dead. Overall, the Strong Buy analyst’s consensus view on IMVT suggests that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which buy 7 and include only a single Hold. The average price target here stands at $ 40.38, which implies that the next 12 months are ~ 121% upside down. (See IMVT stock analysis on TipRanks) Visit TipRanks ‘best-selling stocks, a newly launched tool that combines all of TipRanks’ stock insights to find great ideas for stocks trading at attractive valuations. Disclaimer: The opinions expressed in this article are solely those of the proposed analysts. The content is for informational purposes only. It is very important to do your own analysis before investing.